GENFLEET-B Shares Surge Following Clinical Trial Acceptance and Positive Analyst Coverage

Deep News05-20 11:30

GENFLEET-B (02595) saw its shares rise over 6% during the trading session. At the time of reporting, the stock was up 4.62%, trading at HKD 35.80 with a turnover of HKD 17.952 million.

The latest announcement on the CDE website shows that GENFLEET-B's clinical trial application for the GFS202A injection was officially accepted on May 12, with the acceptance number CXSL2600491. Public information indicates that GFS202A is the world's first bispecific antibody targeting both GDF15 and IL-6.

Southwest Securities Co.,Ltd. (600369) published a research report stating that the company is targeting major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product portfolio, aiming to cover first-line and various subsequent treatments, with its product development progress leading globally. The report forecasts revenues of RMB 85 million, RMB 102 million, and RMB 311 million for 2026, 2027, and 2028, representing year-on-year changes of -35%, +20%, and +205%, respectively. This marks the first coverage by the firm, which recommends active attention to the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192607908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 11:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192607908","market":"us","top_or_hot":-1,"title":"GENFLEET-B Shares Surge Following Clinical Trial Acceptance and Positive Analyst Coverage","media":"Deep News","content":"<p>GENFLEET-B (02595) saw its shares rise over 6% during the trading session. At the time of reporting, the stock was up 4.62%, trading at HKD 35.80 with a turnover of HKD 17.952 million.</p>\n<p>The latest announcement on the CDE website shows that GENFLEET-B's clinical trial application for the GFS202A injection was officially accepted on May 12, with the acceptance number CXSL2600491. Public information indicates that GFS202A is the world's first bispecific antibody targeting both GDF15 and IL-6.</p>\n<p>Southwest Securities Co.,Ltd. (600369) published a research report stating that the company is targeting major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product portfolio, aiming to cover first-line and various subsequent treatments, with its product development progress leading globally. The report forecasts revenues of RMB 85 million, RMB 102 million, and RMB 311 million for 2026, 2027, and 2028, representing year-on-year changes of -35%, +20%, and +205%, respectively. This marks the first coverage by the firm, which recommends active attention to the stock.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENFLEET-B Shares Surge Following Clinical Trial Acceptance and Positive Analyst Coverage</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENFLEET-B Shares Surge Following Clinical Trial Acceptance and Positive Analyst Coverage\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-05-20 11:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENFLEET-B (02595) saw its shares rise over 6% during the trading session. At the time of reporting, the stock was up 4.62%, trading at HKD 35.80 with a turnover of HKD 17.952 million.</p>\n<p>The latest announcement on the CDE website shows that GENFLEET-B's clinical trial application for the GFS202A injection was officially accepted on May 12, with the acceptance number CXSL2600491. Public information indicates that GFS202A is the world's first bispecific antibody targeting both GDF15 and IL-6.</p>\n<p>Southwest Securities Co.,Ltd. (600369) published a research report stating that the company is targeting major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product portfolio, aiming to cover first-line and various subsequent treatments, with its product development progress leading globally. The report forecasts revenues of RMB 85 million, RMB 102 million, and RMB 311 million for 2026, 2027, and 2028, representing year-on-year changes of -35%, +20%, and +205%, respectively. This marks the first coverage by the firm, which recommends active attention to the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0183","symbol_name":"MSCI概念","start_time":0,"source_url":"","article_id":"1192607908","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192607908","pubTimestamp":1779247831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"GENFLEET-B (02595) saw its shares rise over 6% during the trading session. At the time of reporting, the stock was up 4.62%, trading at HKD 35.80 with a turnover of HKD 17.952 million. The latest...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600369":"西南证券","BK0183":"MSCI概念","02595":"劲方医药-B","BK0276":"资本市场","BK0188":"融资融券","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK0012":"证金概念","BK1574":"生物医药B类股","BK0028":"国家队"},"translate_title":"GENFLEET-B股价在临床试验接受和分析师积极报道后飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600369":1,"09939":1,"02595":1},"content_text":"GENFLEET-B (02595) saw its shares rise over 6% during the trading session. At the time of reporting, the stock was up 4.62%, trading at HKD 35.80 with a turnover of HKD 17.952 million.\nThe latest announcement on the CDE website shows that GENFLEET-B's clinical trial application for the GFS202A injection was officially accepted on May 12, with the acceptance number CXSL2600491. Public information indicates that GFS202A is the world's first bispecific antibody targeting both GDF15 and IL-6.\nSouthwest Securities Co.,Ltd. (600369) published a research report stating that the company is targeting major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product portfolio, aiming to cover first-line and various subsequent treatments, with its product development progress leading globally. The report forecasts revenues of RMB 85 million, RMB 102 million, and RMB 311 million for 2026, 2027, and 2028, representing year-on-year changes of -35%, +20%, and +205%, respectively. This marks the first coverage by the firm, which recommends active attention to the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192607908","isCrawlerRequest":true}